|
|
Volumn 85, Issue 2-3, 2002, Pages 195-197
|
|
Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?
|
|
Author keywords
Bosentan; ENABLE Study; Non selective endothelin antagonism
|
|
Indexed keywords
BOSENTAN;
ENDOTHELIN;
ENDOTHELIN RECEPTOR ANTAGONIST;
NEUROHORMONE;
PLACEBO;
VASOCONSTRICTOR AGENT;
CLINICAL TRIAL;
COLLEGE;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE COURSE;
DISEASE MODEL;
DISEASE SEVERITY;
DIURETIC THERAPY;
DRUG MEGADOSE;
FLUID RETENTION;
HEART DISEASE;
HEART FAILURE;
HEART LEFT VENTRICLE EJECTION FRACTION;
HOSPITALIZATION;
HUMAN;
MORBIDITY;
MORTALITY;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RECEPTOR BLOCKING;
REVIEW;
RISK;
UNITED STATES;
ANTIHYPERTENSIVE AGENTS;
HEART FAILURE, CONGESTIVE;
HOSPITALIZATION;
HUMANS;
RANDOMIZED CONTROLLED TRIALS;
RECEPTORS, ENDOTHELIN;
SULFONAMIDES;
TREATMENT OUTCOME;
|
|
EID: 0036774973
PISSN: 01675273
EISSN: None
Source Type: Journal
DOI: 10.1016/S0167-5273(02)00182-1 Document Type: Editorial |
|
Times cited : (280)
|
|
References (8)
|
